<DOC>
	<DOCNO>NCT01954251</DOCNO>
	<brief_summary>The purpose study assess immunogenicity , reactogenicity safety GSK Biologicals ' HZ/su vaccine first dose co-administered FLU-D-QIV vaccine adult age 50 year old compare administration vaccine separately .</brief_summary>
	<brief_title>Study Evaluate Immunogenicity Safety GlaxoSmithKline ( GSK ) Biologicals ' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals ' Seasonal Influenza Vaccine GSK2321138A Adults Aged 50 Years Older</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol ( e.g . completion diary card , return followup visit ) . A male female age 50 year old , time first vaccination study vaccine ( ) . Written inform consent obtain subject . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( define 14 consecutive day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose ( corticosteroid , mean prednisone ≥ 20 mg/day , equivalent ) . A prednisone dose &lt; 20 mg/day allow . Inhaled , topical intraarticular corticosteroid allow . Administration plan administration vaccine foreseen study protocol within period start 30 day first dose study vaccine ( ) ( HZ/su and/or FLUDQIV vaccine ) end 30 day last dose HZ/su vaccine . Administration influenza vaccine six month precede entry study plan administration last blood sample exception FLUDQIV vaccine give study . Administration longacting immunemodifying drug ( e.g . infliximab ) within six month prior first vaccine dose expect administration time study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product ( pharmaceutical product device ) . Previous vaccination VZV HZ and/or plan administration study VZV HZ vaccine ( include investigational nonregistered vaccine ) study vaccine . History HZ . Any confirm suspected immunosuppressive immunodeficient condition result disease ( e.g. , malignancy , HIV infection ) immunosuppressive/cytotoxic therapy ( e.g. , medication use cancer chemotherapy , organ transplantation treat autoimmune disorder ) . History reaction hypersensitivity likely exacerbate component vaccine . History Guillain Barré syndrome . Hypersensitivity latex . Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C /99.5°F oral , axillary tympanic route , ≥ 38.0°C /100.4°F rectal route . The preferred route record temperature study oral . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may , enrol discretion investigator . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution 2 month last dose study vaccine . Any condition , opinion investigator , prevents subject participate study . Any condition , judgment investigator would make intramuscular injection unsafe .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>FLU-D-QIV</keyword>
	<keyword>Adults</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>co-administration</keyword>
	<keyword>Herpes zoster</keyword>
</DOC>